LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Listă Acțiuni・Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Închisă

4.35 -7.45

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

4.32

Maxim

4.37

Indicatori cheie
By Trading Economics
Venit	-29K -20M
Vânzări	701K 2M
EPS	-0.15
Marjă de profit	-993.186
Angajați	69
EBITDA	-2.5M -22M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+144.72% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-27M 606M
Deschiderea anterioară	11.8
Închiderea anterioară	4.35

Aclaris Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2026, 19:20 UTC

Principalele dinamici ale pieței

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 iun. 2026, 23:46 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 iun. 2026, 23:36 UTC

Market Talk

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 iun. 2026, 18:00 UTC

Câștiguri

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 iun. 2026, 12:40 UTC

Achiziții, Fuziuni, Preluări

Correction to Texas Billionaires Article America's Resort -- WSJ

6 iun. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6 iun. 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6 iun. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2026, 00:14 UTC

Achiziții, Fuziuni, Preluări

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 iun. 2026, 21:27 UTC

Câștiguri

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 iun. 2026, 20:19 UTC

Achiziții, Fuziuni, Preluări

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 iun. 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 iun. 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 iun. 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 iun. 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 iun. 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 iun. 2026, 18:33 UTC

Achiziții, Fuziuni, Preluări

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 iun. 2026, 17:50 UTC

Câștiguri

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 iun. 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 iun. 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Aclaris Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

144.72% sus

Prognoză pe 12 luni

Medie 10.67 USD 144.72%

Maxim 16 USD

Minim 4 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAclaris Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Aclaris Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.